News

Material Information- Announcement of the Execution Results of the Company’s Treasury Share Buyback

1.Originally prescribed ceiling on total monetary amount of share repurchase (NTD):3,496,279,112 2.Originally scheduled period for the repurchase:2026/09/07~2026/11/06 3.Originally determined no.of shares to be repurchased (shares):3,000,000 4.Originally determined repurchase price range (NTD):80.00~126.00, should the Company’s share price fall below the lower limit of the trading range, share repurchases will continue. 5.Actual

Material Information- Announcement of the record date for the issuance of restricted employee shares

1.Date of occurrence of the event:2026/11/05 2.Company name: Handa Pharmaceuticals, Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios: NA 5.Cause of occurrence: (1)On June 17, 2025, The Company's Annual General Shareholders’ Meeting approved the issuance of 600,000 restricted employee shares, each having a

Material Information- Announcement of the Board’s Resolution to redeem and cancel restricted employee shares for a capital reduction

1.Date of the board of directors resolution:2026/11/05 2.Reason for capital reduction: Restricted shares granted to employees who fail to meet the vesting conditions will be redeemed without consideration and canceled for capital reduction in accordance with the issuance rules. 3.Amount of capital reduction: NTD 105,000 4.Cancelled shares:10,500 shares 5.Capital

Material Information- Announcement on behalf of the subsidiary, Handa Pharma, Inc, regarding the change in over one-third of directors

1.Date of occurrence of the change:2026/11/05 2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): Institutional director 3.Title and name of the previous position holder: George Kraft 4.Resume of the previous position holder: Vice President of Corporate Development Department of

Material Information- Announcement of the Board of Directors approved the consolidated financial statements for 2026 Q3.

1.Date of the board of directors submitted or approved:2026/11/05 2.Date of the audit committee approved:2026/11/05 3.Start and end dates of financial reports or unaudited financial information of the reporting period (XXXX/XX/XX~XXXX/XX/XX):2026/01/01~2026/09/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):630,365 5.Gross profit (loss) from operations accumulated

Material Information- Announces Handa Pharmaceuticals, Inc., and on behalf of the subsidiaries, regarding the 505(b)(2) new formulation drug HND-039 patent infringement lawsuit

1.Parties to the legal matter: Plaintiff:Exelixis, Inc Defendant:Handa Pharmaceuticals, Inc., Handa Pharma, Inc. and Handa Oncology, LLC 2.Name of the court or punishing agency of the legal matter: United States District Court for DELAWARE 3.Reference/Case number of relevant documents of the legal matter: NO. 1:26-cv-01412-UNA 4.Date of occurrence of the event:2026/11/04 5.Details of

Material Information-The Company was invited to attend the in-person and virtual institutional investor conference hosted by First Securities

1.Date of institutional investor conference:2026/11/11 2.Time of institutional investor conference:14:30 3.Location of institutional investor conference: (1)In-person investor conference: 2F., No. 35, Sec. 1, Chang’an E. Rd., Zhongshan Dist., Taipei City (2) Virtual investor conference: Webex 4.Outline of institutional investor conference: (1)The Company was invited to attend the in-person and virtual institutional

Material Information- The Company was invited to attend the in-person meeting hosted by KGI Securities

1.Date of institutional investor conference:2026/09/16 2.Time of institutional investor conference:14:30 3.Location of institutional investor conference:No. 700, Mingshui Road, Zhongshan District, Taipei City 4.Outline of institutional investor conference:The Company was invited to attend the in-person meeting hosted by KGI Securities to discuss information previously disclosed by the Company. 5.Any other